Discovery/R&D

  1. Engineering Proteins For Food Allergies With Ukko's Dr. Anat Binur 10/25/2022

    Anat Binur, Ph.D. is CEO and Co-Founder at Ukko, where she's leading an effort to create new allergy therapeutics by engineering the proteins that induce immune response in people who suffer from food allergies. The effort at Ukko is deeply rooted in computational biology. The company leverages artificial intelligence to analyze how the allergen proteins interact with patients' blood in an effort to determine the specific attributes of the proteins that trigger immune response. Then, it applies a unique combination of compute power and biology to identify and understand the changes it wants to engineer and predict the best possible designs. Learn how Ukko is fostering a culture of IT and biology collaboration and what lured this dynamic entrepreneur into biopharma on this episode of the Business of Biotech.

  2. Maximizing mRNA With Precision Nanosystems' James Taylor, Ph.D. 11/8/2021

    Dr. James Taylor believes that genomic medicine will prove the most revolutionary thing the life sciences industries have ever seen, and that it will ultimately become the largest therapeutic class. Dr. Taylor is president and CEO at Precision Nanosystems. He chalks up the genomic nature of biology, the fact that genomes are information-based, the breadth and validation of the genomic medicine toolbox, and the democratization of genomic medicine development as reasons to be bullish. Join Dr. Taylor and me for a conversation on why RNA and DNA delivery are game-changers, and what Precision Nanosystems is doing to push the ball downfield.

  3. Cannabinoid And Psychedelic Combinations With Incannex Healthcare's Joel Latham 9/19/2025

    On this week's Business Of Biotech episode, Joel Latham, President and CEO at Incannex Healthcare, talks about developing cannabinoid and psychedelic combination therapies for conditions as diverse as sleep apnea, rheumatoid arthritis, and generalized anxiety disorder.

  4. Celyad CEO Filippo Petti On In-House Allogeneic Cell Therapy Manufacturing 2/8/2021

    Join Matt Pillar and Erin Harris as we catch up with Celyad Oncology chief Filippo Petti on his company's differentiated approach to the discovery and development of allogeneic CAR-T cell therapy candidates for the treatment of cancer. Petti shares the technology and how the company intends to scale in-house manufacturing in its Belgium-based manufacturing facility.

  5. Circular RNA with Orna Therapeutics' Tom Barnes, Ph.D. and Advancing RNA's Anna Rose Welch 4/28/2024

    As if Orna Therapeutics' CEO, Thomas Barnes, isn't enough to draw you in to the Business of Biotech, we teamed up with Advancing RNA Editorial & Community Director Anna Rose Welch to co-host this week's episode. Together, Anna Rose and I press Dr. Barnes on his transition from academia to biotech, the therapeutic proposition of circular, or "O", RNA and why it holds great potential to best linear RNA constructs, the novel, platform- and partnership-based approaches Orna is taking to address B-cell lymphomas and Duchenne Muscular Dystrophy, viral vector and lipid nanoparticle complexity, and a whole lot more.

  6. Gynecological Cancer Therapies With Context Therapeutics' Martin Lehr 4/18/2022

    Context Therapeutics Co-Founder & CEO Martin Lehr shares stories from his self-described "recovery from venture capital," the work his company is doing in gynecological cancers, and how his small company manages a modality-agnostic approach and investigator-sponsored trials across multiple clinical candidates, four of which are in phase 2 clinical trials. We also discuss his "extracurricular" work with BioBreak, Life Science Leader, and Life Science Cares, and why those organizations are important to him personally and professionally.

  7. An AI Awakening With Profluent Bio's Hilary Eaton, Ph.D. 9/22/2024

    Hilary Eaton, Ph.D. was a self-described AI skeptic, particularly regarding using the tool in drug discovery. Then, a series of professional and deeply personal life events and medical discoveries put her in a position to confront that skepticism head-on. On Business of Biotech, the Chief Business Officer at ProFluent Bio shares her story and makes a pragmatic case for the transformative value of AI to biotech builders.

  8. BoB In South Florida: Anthony Japour, M.D., iTolerance 10/16/2025

    On this week's episode of the Business of Biotech, Anthony Japour, M.D., CEO at iTolerance, talks about his work as a physician treating infectious diseases, his CEO role in diagnostics at the height of the COVID-19 pandemic, what he learned working as a medical director at a large CRO, and iTolerance's work toward a cure for Type 1 diabetes that doesn't require chronic immunosuppression.

  9. The Antibody Engine With Abpro's Chan Brothers 12/5/2022

    In an industry that takes new business naming conventions to etymological extremes, Abpro is a refreshingly clear exception. Brothers Ian Chan (CEO & Co-Founder) and Eugene Chan, M.D., (Chairman & Co-Founder) are antibody pros. The company's pipeline spans no fewer than 8 antibody candidates aimed at COVID-19, cancers including breast, gastric, and liver, and ophthalmologic indications DME and wet AMD. With a scientific advisory board led by Bob Langer, Ph.D. of Moderna fame and a new partnership with global powerhouse Celltrion worth a potential $1.75 billion, the company's on the move. On this episode of the Business of Biotech, the Chan brothers take us behind the scenes of Abpro's progress.

  10. Next-Gen Nanobodies With MoonLake's Jorge Santos Da Silva, Ph.D. 3/27/2023

    The more we learn about inflammation and the complex cause/contributor/symptom roles it plays in various disease states, the more business activity we see in the inflammation therapeutics space. But to date, commercial pharmaceutical and biologic efforts have fallen short for patients, says Moonlake Immunotherapeutics CEO Jorge Santos Da Silva, Ph.D. What's the problem, and why does he think his camelid-derived nanobody candidates are poised to outperform big-pharma standards from the likes of UCB and Novartis? Find out on this week's episode of the Business of Biotech.